Lamotrigine
Lamictal (lamotrigine) is a small molecule pharmaceutical. Lamotrigine was first approved as Lamictal on 1994-12-27. It is used to treat bipolar disorder, epilepsy, lennox gastaut syndrome, mood disorders, and partial epilepsies amongst others in the USA. It is known to target sodium channel protein type 2 subunit alpha.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Trade Name
FDA
EMA
Lamictal (generic drugs available since 2009-01-22)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lamictal | New Drug Application | 2023-02-09 |
| lamotrigine | ANDA | 2023-06-20 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bipolar disorder | EFO_0000289 | D001714 | F30.9 |
| epilepsy | EFO_0000474 | D004827 | G40.9 |
| lennox gastaut syndrome | — | D065768 | G40.81 |
| mood disorders | EFO_0004247 | D019964 | F30-F39 |
| partial epilepsies | EFO_0004263 | D004828 | — |
| seizures | HP_0007359 | D012640 | G40.4 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
182 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 5 | 3 | 14 | 15 | 11 | 47 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 10 | 3 | 10 | 9 | 13 | 44 |
| Healthy volunteers/patients | — | 19 | — | — | 1 | 1 | 21 | ||
| Depression | D003863 | F33.9 | — | — | 2 | 3 | 2 | 7 | |
| Partial epilepsies | D004828 | EFO_0004263 | — | — | 4 | 3 | — | 7 | |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 3 | 1 | 1 | 5 |
| Psychotic disorders | D011618 | F20.81 | — | 1 | — | 1 | 1 | 3 | |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | 1 | 1 | 1 | 3 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 1 | 1 | 1 | — | 3 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | 1 | 2 | 3 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Seizures | D012640 | G40.4 | 2 | 1 | 2 | — | 1 | 5 | |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | 1 | 1 | — | — | 2 |
| Vertigo | D014717 | H81.39 | — | 1 | 1 | — | — | 2 | |
| Meniere disease | D008575 | EFO_0006862 | H81.0 | — | 1 | 1 | — | — | 2 |
| Trigeminal neuralgia | D014277 | EFO_1001219 | G50.0 | — | 1 | 1 | — | 1 | 2 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | 1 | 1 | — | — | 2 |
| Dementia | D003704 | F03 | — | — | 1 | — | — | 1 | |
| Psychophysiologic disorders | D011602 | F45.9 | — | — | 1 | — | — | 1 | |
| Neurofibromatosis 1 | D009456 | Q85.01 | — | 1 | 1 | — | — | 1 | |
| Myotonic disorders | D020967 | Orphanet_606 | G71.1 | — | — | 1 | — | — | 1 |
Show 10 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | 1 | — | — | — | 1 | |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | — | — | — | 1 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 1 | — | — | — | 1 |
| Neurotic disorders | D009497 | F48.9 | — | 1 | — | — | — | 1 | |
| Chronic progressive multiple sclerosis | D020528 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mental disorders | D001523 | EFO_0000677 | F91.9 | 4 | — | — | — | — | 4 |
| Therapeutic equivalency | D013810 | 2 | — | — | — | — | 2 | ||
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic pain | D059350 | HP_0012532 | — | — | — | — | 1 | 1 | |
| Suicidal ideation | D059020 | EFO_0004320 | R45.851 | — | — | — | — | 1 | 1 |
| Emotions | D004644 | — | — | — | — | 1 | 1 | ||
| Morbid obesity | D009767 | EFO_0001074 | — | — | — | — | 1 | 1 | |
| Facial nerve diseases | D005155 | G51 | — | — | — | — | 1 | 1 | |
| Breast feeding | D001942 | — | — | — | — | 1 | 1 | ||
| Pregnancy rate | D018873 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LAMOTRIGINE |
| INN | lamotrigine |
| Description | Lamotrigine is a member of the class of 1,2,4-triazines in which the triazene skeleton is substituted by amino groups at positions 3 and 5, and by a 2,3-dichlorophenyl group at position 6. It has a role as an anticonvulsant, an antimanic drug, an antidepressant, a non-narcotic analgesic, a calcium channel blocker, an excitatory amino acid antagonist, an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor, an environmental contaminant, a xenobiotic and a geroprotector. It is a member of 1,2,4-triazines, a primary arylamine and a dichlorobenzene. |
| Classification | Small molecule |
| Drug class | sodium channel blockers, signal transduction modulators |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1 |
Identifiers
| PDB | — |
| CAS-ID | 84057-84-1 |
| RxCUI | 28439 |
| ChEMBL ID | CHEMBL741 |
| ChEBI ID | 6367 |
| PubChem CID | 3878 |
| DrugBank | DB00555 |
| UNII ID | U3H27498KS (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SCN2A
SCN2A
Organism
Homo sapiens
Gene name
SCN2A
Gene synonyms
NAC2, SCN2A1, SCN2A2
NCBI Gene ID
Protein name
sodium channel protein type 2 subunit alpha
Protein synonyms
HBSC II, Sodium channel protein brain II subunit alpha, Sodium channel protein type II subunit alpha, sodium channel protein, brain type 2 alpha subunit, sodium channel, voltage-gated, type II, alpha 1 polypeptide, sodium channel, voltage-gated, type II, alpha 2 polypeptide, sodium channel, voltage-gated, type II, alpha subunit, voltage-gated sodium channel subtype II, Voltage-gated sodium channel subunit alpha Nav1.2, voltage-gated sodium channel type II alpha subunit
Uniprot ID
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 14,961 documents
View more details
Safety
Black-box Warning
Black-box warning for: Lamictal, Lamotrigine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,422 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more